CDEK
← Mechanisms of action

TNFRSF17

SINGLE PROTEINHomo sapiens
Preferred name: Tumor necrosis factor receptor superfamily member 17 ChEMBL ↗

Linked proteins

Drugs acting on this target (26)

Active Pharmaceutical Ingredient Mechanism Type ▲ Approval Status API Type Mechanism of Action
amg 420AdccexperimentalmAbTNFRSF17 adcc
amg 701AdccexperimentalmAbTNFRSF17 adcc
bi 836909AdccexperimentalmAbTNFRSF17 adcc
cc-93269AdccexperimentalmAbTNFRSF17 adcc
cc-95266AdccexperimentalmAbTNFRSF17 adcc
cc-99712AdccexperimentalmAbTNFRSF17 adcc
gsk2857916AdccexperimentalmAbTNFRSF17 adcc
hpn217AdccexperimentalmAbTNFRSF17 adcc
linvoseltamab (Lynozyfic)AdccapprovedmAbTNFRSF17 adcc
medi2228AdccexperimentalmAbTNFRSF17 adcc
regn5459AdccexperimentalmAbTNFRSF17 adcc
ro7297089AdccexperimentalmAbTNFRSF17 adcc
sea-bcmaAdccexperimentalmAbTNFRSF17 adcc
tnb-383bAdccexperimentalmAbTNFRSF17 adcc
belantamab mafodotin (TECVAYLI)AntagonistapprovedmAbTNFRSF17 antagonist
belantamab mafodotin (TECVAYLI)Binding agentapprovedmAbTumor necrosis factor receptor superfamily member 17 binding agent
ciltacabtagene autoleucel (Carvykti)Binding agentapprovedCell therapyTumor necrosis factor receptor superfamily member 17 binding agent
Elranatamab (Elrexfio)Binding agentapprovedmAbTumor necrosis factor receptor superfamily member 17 binding agent
emb-06Binding agentexperimentalmAbBCMA
hdp-101Binding agentexperimentalmAbBCMA
idecabtagene vicleucel (Abecma)Binding agentapprovedSmall moleculeTumor necrosis factor receptor superfamily member 17 binding agent
teclistamab (Tecvayli)Binding agentapprovedmAbTumor necrosis factor receptor superfamily member 17 binding agent
amg 224Immunity, passiveexperimentalmAbTNFRSF17 immunity, passive
bcma car-nk cellsImmunity, passiveexperimentalCell therapyTNFRSF17 immunity, passive
cd269 car-T cellsImmunity, passiveexperimentalCell therapyTNFRSF17 immunity, passive
teplizumab (Tzield)Immunity, passiveapprovedmAbTNFRSF17 immunity, passive